Omadacycline: A Potential Fluoroquinolone Replacement?
OCT 03, 2018 | CONTAGION® EDITORIAL STAFF
Jason Gallagher, PharmD: Omadacycline is another novel tetracycline that is being developed. This one is pursuing indications for complicated skin infections and for community-acquired pneumonia. Now, as a novel tetracycline, I kind of see it as a potential fluoroquinolone replacement in the treatment of community-acquired pneumonia and some other mixed infections such as the skin and soft tissue infections that have been developed.
With some of the warnings that have come out discouraging fluoroquinolone use for certain indications—warnings from the US Food and Drug Administration that are fairly strong—other options [are limited]. Now, many of those other options when they work, are cheap, inexpensive generic antibiotics that should be used. But for the more resistant infections, where sometimes something else is needed, omadacycline could potentially be an agent that we use, and it should be available orally which would be a significant plus compared with most of the other drugs that have been developed in the past 5 to 6 years.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512